Send to

Choose Destination
Oncoimmunology. 2013 Mar 1;2(3):e23430.

Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination.

Author information

INSERM; Unité Mixte de Recherche 1098; Besançon, France ; Etablissement Français du Sang de Bourgogne Franche-Comté; UMR1098; Besançon, France ; Université de Franche-Comté; UMR1098; SFR IBCT; Besançon, France.


Accumulating evidence demonstrates the importance of CD4+ T cells in antitumor immune responses. Identifying promiscuous MHC class II-binding peptides derived from relevant tumor-associated antigens that specifically target CD4+ helper T cells in vivo represent a powerful approach to fully exploit these cells for anticancer immunotherapy.


CD4 T cell; cancer vaccine; helper peptide; immunotherapy; telomerase

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center